Abstract
Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Volume: 12 Issue: 3
Author(s): Pinar Kuru and Mehmet Agirbasli
Affiliation:
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Abstract: Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Export Options
About this article
Cite this article as:
Kuru Pinar and Agirbasli Mehmet, Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692112666141027231225
DOI https://dx.doi.org/10.2174/1875692112666141027231225 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Meet Our Editorial Board Member
Current Vascular Pharmacology Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Vitamin D Supplementation: Its Relevance to Obesity, Atopic Dermatitis and Depression)
Current Nutrition & Food Science Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews New Hybrid Method for Left Ventricular Ejection Fraction Assessment from Radionuclide Ventriculography Images
Current Medical Imaging Medicinal Chemistry of Drugs Used in Diabetic Cardiomyopathy
Current Medicinal Chemistry A Study of Prescription Pattern and Compliance of Anti-hypertensives with the Treatment Guidelines in Aseer Region; Saudi Arabia
Current Drug Therapy Advances in Drug Safety
Current Pharmaceutical Design Azimilide, A Novel Oral Class III Antiarrhythmic for Both Supraventricular and Ventricular Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation
Current Pharmacogenomics and Personalized Medicine Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions
Current Protein & Peptide Science Alternative Therapies for Diabetes: A Comparison of Western and Traditional Chinese Medicine (TCM) Approaches
Current Diabetes Reviews Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry